Vinorelbine combined with cisplatin treatment the clinical efficacy of advanced esophageal cancer.docVIP

 PAGE \* MERGEFORMAT 22 Vinorelbine combined with cisplatin treatment the clinical efficacy of advanced esophageal cancer Authors: SUN, Qin days clean, Ruan Zhi-ping, Wang Hao, Ma Jinlu 【Abstract】 Objective To observe the NVB (NVB) and cisplatin (CDDP) of the NP in the treatment of esophageal cancer efficacy and toxicity. Methods 46 cases of esophageal cancer patients with NP treatment program, which NVB 25 ~ 30mg/m2, intravenous infusion, d1, d8 administration; DDP 30mg/m2, into the vein, d1 ~ 3 administration, 21 ~ 28 days of a cycle, each case was treated for at least 2 cycles. Results 46 patients, overall response rate (RR) was 45.7% (21/46), of which CR2.2% (1 / 46), PR43.5% (20/46), SD34.8% (16/46) , PD19.6% (9 / 46), the median survival time 9.6 months (2 ~ 24 months), the main toxicities were myelosuppression and gastrointestinal reactions. Conclusion of Vinorelbine Combined with Cisplatin in the Treatment esophageal cancer accurate, toxicity can be tolerated. Keywords: esophageal cancer Vinorelbine and cisplatin combination chemotherapy Clinical Study of Vinorelbine Combined with Cisplatin in the Treatment of Advanced Esophageal Cancer Keywords:: Vinorelbine; Cisplatin; Esophageal cancer; Combined modality therapy Gaynor, that is made Navelbine (vinorelbine, NVB), is the mitotic cell cycle specific drugs, it has a number of tumors were valid, such as non-small cell lung cancer, breast cancer, ovarian cancer, lymphoma, head and neck cancer, etc. . We apply the NP program (vinorelbine combined with cisplatin) in our hospital from March 2001 to March 2003 to 46 cases of recurrence and metastasis in patients with advanced esophageal cancer chemotherapy, and achieved good effect, are summarized below. 1 Data and methods 1.1 Clinical data: 46 cases in patients with advanced esophageal cancer were diagnosed by pathology, there are measurable lesion, Karnofsky 70 points above the expected lifetime of more t